New cancer drug beats chemotherapy in study

New data from the first of a new type of cancer drug suggest its benefits and limitations, while leaving room for other candidates looking to enter the lucrative market.

Amgen Inc.’s lung cancer pill Lumakras beat out standard chemotherapy in a late-stage study, helping patients survive without their tumors getting worse, although it failed to prove it reduced the number of deaths, the company said.